IL218329A0 - A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) - Google Patents
A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)Info
- Publication number
- IL218329A0 IL218329A0 IL218329A IL21832912A IL218329A0 IL 218329 A0 IL218329 A0 IL 218329A0 IL 218329 A IL218329 A IL 218329A IL 21832912 A IL21832912 A IL 21832912A IL 218329 A0 IL218329 A0 IL 218329A0
- Authority
- IL
- Israel
- Prior art keywords
- duloxetine
- naphthyloxy
- thienyl
- crystallization
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2009-584A CZ304602B6 (en) | 2009-09-02 | 2009-09-02 | Crystallization process of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine hydrochloride) |
| PCT/CZ2010/000099 WO2011026449A1 (en) | 2009-09-02 | 2010-09-02 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218329A0 true IL218329A0 (en) | 2012-04-30 |
Family
ID=43413356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218329A IL218329A0 (en) | 2009-09-02 | 2012-02-27 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2473497A1 (en) |
| JP (1) | JP2013503823A (en) |
| KR (1) | KR20120047262A (en) |
| CN (1) | CN102482254A (en) |
| BR (1) | BR112012004862A2 (en) |
| CZ (1) | CZ304602B6 (en) |
| EA (1) | EA021528B1 (en) |
| IL (1) | IL218329A0 (en) |
| MX (1) | MX2012002621A (en) |
| WO (1) | WO2011026449A1 (en) |
| ZA (1) | ZA201201570B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626735A (en) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术（石家庄）有限公司 | Duloxetine hydrochloride crystal form and preparation method thereof |
| CN104478849A (en) * | 2014-02-14 | 2015-04-01 | 广东东阳光药业有限公司 | Method for preparing noradrenaline reuptake dual inhibitor |
| CN106265528A (en) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | Method for preparing drug aggregate |
| JP2016222628A (en) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | Method for producing duloxetine hydrochloride |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007433A (en) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-aryloxy-3-substituted propanamine |
| US5362886A (en) | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| DE10212301A1 (en) | 2002-03-20 | 2003-10-02 | Bayer Ag | Process for the preparation of aryl aminopropanols |
| ATE444949T1 (en) | 2002-07-09 | 2009-10-15 | Lonza Ag | METHOD FOR PRODUCING N-MONOAKYL-BETA-AMINOAL ALCOHOLS |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| CZ297560B6 (en) * | 2004-10-26 | 2007-02-07 | Zentiva, A. S. | Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) |
| EP1874754A1 (en) * | 2005-03-14 | 2008-01-09 | Teva Pharmaceutical Industries Ltd | Pure duloxetine hydrochloride |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| GB0612508D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| GB0612509D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| CZ300116B6 (en) * | 2006-12-05 | 2009-02-11 | Zentiva, A. S. | Purification process of (S)-N-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride |
| US8269023B2 (en) * | 2007-03-05 | 2012-09-18 | Lupin Ltd. | Process for preparation of duloxetine hydrochloride |
-
2009
- 2009-09-02 CZ CZ2009-584A patent/CZ304602B6/en not_active IP Right Cessation
-
2010
- 2010-09-02 EA EA201290127A patent/EA021528B1/en not_active IP Right Cessation
- 2010-09-02 EP EP10771629A patent/EP2473497A1/en not_active Withdrawn
- 2010-09-02 WO PCT/CZ2010/000099 patent/WO2011026449A1/en not_active Ceased
- 2010-09-02 BR BR112012004862A patent/BR112012004862A2/en not_active IP Right Cessation
- 2010-09-02 JP JP2012527196A patent/JP2013503823A/en active Pending
- 2010-09-02 KR KR1020127004225A patent/KR20120047262A/en not_active Withdrawn
- 2010-09-02 CN CN2010800392370A patent/CN102482254A/en active Pending
- 2010-09-02 MX MX2012002621A patent/MX2012002621A/en not_active Application Discontinuation
-
2012
- 2012-02-27 IL IL218329A patent/IL218329A0/en unknown
- 2012-03-01 ZA ZA2012/01570A patent/ZA201201570B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011026449A1 (en) | 2011-03-10 |
| BR112012004862A2 (en) | 2015-09-08 |
| ZA201201570B (en) | 2013-08-28 |
| EA201290127A1 (en) | 2013-02-28 |
| CN102482254A (en) | 2012-05-30 |
| JP2013503823A (en) | 2013-02-04 |
| MX2012002621A (en) | 2012-07-03 |
| CZ304602B6 (en) | 2014-07-30 |
| EA021528B1 (en) | 2015-07-30 |
| CZ2009584A3 (en) | 2011-03-09 |
| KR20120047262A (en) | 2012-05-11 |
| EP2473497A1 (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2513434T3 (en) | Cam unit for a constructed camshaft | |
| GB2461132B (en) | Method of data delivery across a network | |
| GB2470675B (en) | Method of data delivery across a network | |
| IL230600A (en) | Method for producing 4-(piperidin-1-yl)-benzo[b]thiophene and its derivatives | |
| PL2379299T3 (en) | Method of filling a casing | |
| IL208056A (en) | Method of accessing a model of a substrate | |
| IL183245A0 (en) | Process for preparing phamaceutically acceptable salts of duloxetine and intermediates thereof | |
| GB0808862D0 (en) | A method of data delivery across a network | |
| ZA201203115B (en) | Method for producing a mouthpiece cover of a cigaratte | |
| IL242104A0 (en) | A crystalline form of (r)-7- chloro- n-(quinuclidin-3-yl)benzo[b] thiophene-2- carboxamide hydrochloride monohydrate | |
| AP3169A (en) | A method of improved positioning | |
| EP2465293A4 (en) | Handover method for reducing the amount of data forwarded to a target node | |
| PL2359546T3 (en) | Method for configuring parameters for managing data packets pertaining to a data flow | |
| IL218329A0 (en) | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) | |
| EP2328815A4 (en) | Method of forming a pouch | |
| IL191921A0 (en) | A novel process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate | |
| GB0700830D0 (en) | Crystalline duloxetine hydrochloride | |
| EP2016066A4 (en) | Process for preparing duloxetine | |
| EP2300108A4 (en) | A method for designing a golf club | |
| GB0815458D0 (en) | Method of transferring timing information over packet network | |
| PL2244188T3 (en) | Method for verifying correct data transfer to a video memory | |
| GB0612508D0 (en) | Crystalline duloxetine hydrochloride | |
| WO2008093360A3 (en) | A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride | |
| IL195059A0 (en) | Process for preparing duloxetine and intermediates thereof | |
| GB0612506D0 (en) | Crystalline duloxetine hydrochloride |